Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600409 | 0.86 | TACR1 (0.38) | TACR1ALDH1A1CETP | |
| SCHEMBL29179953 | 0.73 | SLC6A4 (0.43) | SLC6A4SLC6A2ALDH1A1HTR2AKCNH2 | |
| SCHEMBL30858772 | 0.73 | SLC6A4 (0.43) | SLC6A4SLC6A2ALDH1A1HTR2AKCNH2 | |
| SCHEMBL28034152 | 0.72 | CHRNB2 (0.43) | TACR1ALDH1A1 | |
| SCHEMBL1587866 | 0.72 | CETP (0.69) | CETP | |
| SCHEMBL1599550 | 0.72 | TACR1 (0.54) | SLC6A4SLC6A2TACR1ALDH1A1HTR2A | |
| SCHEMBL4236353 | 0.72 | SLC6A4 (0.61) | SLC6A4SLC6A2HTR2AKCNH2HTT | |
| SCHEMBL11568753 | 0.71 | ALDH1A1 (0.42) | SLC6A4SLC6A2ALDH1A1HTR2AKCNH2 | |
| SCHEMBL10656350 | 0.70 | SLC6A4 (0.48) | SLC6A4SLC6A2ALDH1A1HTR2AKCNH2 | |
| SCHEMBL1600725 | 0.70 | SLC6A4 (0.37) | SLC6A4SLC6A2TACR1HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994015-B1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PROD INC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8383660-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-7919506-B2 | Dibenzyl amine compounds and derivatives | PFIZER INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1996564-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Incorporated (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994015-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | Pfizer Products Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007105050-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007105049-A1 | DIBENZYL AMINE DERIVATIVES AS CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | PFIZER INC | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213314-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | SLC6A4 1459/4885SLC6A2 949/4885TACR1 2334/4885 |
| US-20070213371-A1 | Dibenzyl Amine Compounds and Derivatives | APOB, LDLR, CETP | SLC6A4 1459/4885SLC6A2 949/4885TACR1 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.